Group 1 - The core viewpoint of the articles highlights the financial performance and market position of David Medical, indicating a significant decline in revenue and profit in the latest quarterly report [1][2] - As of July 24, David Medical's stock closed at 13.3 yuan, with a PE ratio of 91.80, marking a new low in 88 days, and a total market capitalization of 3.83 billion yuan [1] - The average PE ratio for the medical device industry is 54.55, with a median of 37.54, positioning David Medical at 104th place in the industry ranking [1][2] Group 2 - For Q1 2025, David Medical reported a revenue of 121 million yuan, reflecting a year-on-year decrease of 22.00%, and a net profit of 22.57 million yuan, down 40.78% year-on-year [2] - The company's gross profit margin stands at 57.13%, indicating its ability to maintain profitability despite declining revenues [2] - David Medical specializes in obstetric and pediatric care equipment, minimally invasive surgical instruments, and emergency ICU products, with a range of key products including incubators and neonatal monitoring devices [1]

证券代码：300314 证券简称：戴维医疗 公告编号：2025-038 宁波戴维医疗器械股份有限公司 关于公司申报医疗器械注册获得受理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）于近日取得1 项由国家药品监督管理局颁发的《受理通知书》，受理号为：CQZ2501333。 具体情况如下： 2025年7月24日 呼吸机是一种关键的生命支持类医疗设备，主要用于辅助或替代患者 自主呼吸功能。其核心作用是通过向患者肺部输送精确配比的空氧混合气 体，协助完成气体交换过程（即吸入氧气和排出二氧化碳），从而维持生 命体征稳定或促进患者康复。本次申报产品为电动电控型呼吸机，具备多 种临床适用的通气模式，包括有创通气、无创通气以及高流量氧疗模式， 适用于患者治疗的各个阶段，从无自主呼吸的紧急抢救直至逐步撤机的康 复过程。该产品还集成了脉搏血氧饱和度监测与呼气末二氧化碳监测功能， 能够实时、连续地评估患者的氧合与通气状态，通过这些关键生理参数的 动态监测，临床医生可以更精准地调整呼吸机设置。 上述医疗器械产品目前所处的审批阶 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of David Medical, indicating a decline in revenue and profit, alongside a high PE ratio compared to industry averages [1][2] - As of July 16, David Medical's stock closed at 12.96 yuan, with a PE ratio of 89.46, marking a new low in 80 days, and a total market capitalization of 3.732 billion yuan [1] - The company experienced a net outflow of 7.8469 million yuan in principal funds on July 16, with a total outflow of 18.6796 million yuan over the past five days [1] Group 2 - In the latest quarterly report for Q1 2025, David Medical reported an operating income of 121 million yuan, a year-on-year decrease of 22.00%, and a net profit of 22.5677 million yuan, down 40.78% [2] - The company's gross profit margin stands at 57.13% [2] - David Medical operates in the medical device sector, focusing on obstetric and pediatric care equipment, minimally invasive surgical instruments, and emergency ICU products [1]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 证券代码：300314 证券简称：戴维医疗 公告编号：2025-037 宁波戴维医疗器械股份有限公司 关于全资子公司医疗器械注册证变更的公告 宁波戴维医疗器械股份有限公司（以下简称"公司"）全资子公司宁 波维尔凯迪医疗器械有限公司（以下简称"维尔凯迪"）于近日取得由浙 江省药品监督管理局颁发的1项《医疗器械变更注册（备案）文件》，公 司产品一次性使用包皮切割吻合器完成了医疗器械产品注册变更，具体情 况如下： 产品名称：一次性使用包皮切割吻合器 注册证编号：浙械注准20232022068 批准日期：2025年7月10日 变更内容： 一、型号、规格由"PCS-A-13、PCS-A-15、PCS-A-17、PCS-A-22、PCS-A-26、 PCS-A-30、PCS-A-34、PCS-B-13、PCS-B-15、PCS-B-17、PCS-B-22、PCS-B-26、 PCS-B-30、PCS-B-34、PCS-C-13、PCS-C-15、PCS-C-17、PCS-C-22、PCS-C-26、 PCS-C-30、PCS ...

证券代码：300314 证券简称：戴维医疗 公告编号：2025-036 宁波戴维医疗器械股份有限公司 关于全资子公司申报医疗器械注册获得受理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）全资子公司宁波 维尔凯迪医疗器械有限公司（以下简称"维尔凯迪"）于近日取得由浙江省 药品监督管理局颁发的1项《受理通知书》，受理号为：械受20254020683。 具体情况如下： | 序号 | 产品名称 | 注册分类 | | 临床用途 | | --- | --- | --- | --- | --- | | 1 | 一次性使用胃管 | II | 类 | 插入胃部，排空、清洗、灌注用。 | 维尔凯迪开发的一次性使用胃管与相关的肠胃给药器配合或靠液体重力， 在导管内形成正压或负压。胃管经食道插入至远端胃窦，可用于气体、液体 或流质营养的输入、排（吸）液等，还可用于胃部冲洗。宝塔接头有扣盖， 有利于保持清洁。外壁带有数字刻度和管壁带有 X 光显影标记线，两者均可 有效控制产品的使用长度，助力医疗团队为患者制定个性化治疗方案，推动 ...

Company Overview - David Medical's closing price on July 4 was 12.77 yuan, down 1.01%, with a rolling PE ratio of 88.15 times and a total market value of 3.678 billion yuan [1] - The company ranks 105th in the medical device industry, which has an average PE ratio of 51.05 times and a median of 36.62 times [1] Financial Performance - For Q1 2025, the company reported revenue of 121 million yuan, a year-on-year decrease of 22.00%, and a net profit of 22.57 million yuan, down 40.78% year-on-year [2] - The sales gross margin was reported at 57.13% [2] Shareholding Structure - As of the Q1 2025 report, there are 2 institutional investors holding shares in David Medical, including 1 QFII and 1 insurance company, with a total holding of 1.2529 million shares valued at 1.5 million yuan [1] Product Portfolio - David Medical specializes in obstetric and pediatric care equipment, minimally invasive surgical instruments, and emergency ICU products, including incubators, radiant warmers, jaundice treatment devices, and various monitoring and therapeutic equipment [1] Industry Recognition - The company has been recognized as a "Manufacturing Industry Single Champion Cultivation Enterprise" by the Ministry of Industry and Information Technology and has received multiple honors, including "Famous Brand in Zhejiang Province" and "AAA Credit Rating Enterprise" [1]

| 序号 | 产品名称 | 注册证编号 | 注册证有效期至 | 注册分类 | 适用范围 | | --- | --- | --- | --- | --- | --- | | 1 | 医用电动吸引 | 浙械注准 | 2031.1.4 | Ⅱ类 | 产品与医用导管 | | | 器 | 20162140332 | | | 配套使用，供临床 | | | | | | | 吸取新生儿粘液 | | | | | | | 及新生儿羊水之 | | | | | | | 用。 | 本次延续注册的完成，使得公司可以继续生产和销售医用电动吸引器， 对公司未来经营将产生积极影响。上述产品的实际销售情况取决于未来市 场推广效果，公司目前尚无法预测其对公司未来业绩的影响，敬请投资者 注意投资风险。 特此公告。 宁波戴维医疗器械股份有限公司 证券代码：300314 证券简称：戴维医疗 公告编号：2025-035 宁波戴维医疗器械股份有限公司 关于公司部分医疗器械产品完成延续注册的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）于近日取得由 浙江 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of David Medical, indicating a significant decline in revenue and profit in the latest quarter [1][2] - As of June 30, David Medical's stock closed at 12.7 yuan, with a PE ratio of 87.66, which is significantly higher than the industry average of 50.61 [1][2] - The company has a total market capitalization of 36.58 billion yuan, ranking 105th in the medical device industry based on PE ratio [1][2] Group 2 - In the first quarter of 2025, David Medical reported an operating income of 1.21 billion yuan, a year-on-year decrease of 22.00%, and a net profit of 22.57 million yuan, down 40.78% [2] - The company's sales gross margin stands at 57.13%, indicating a relatively high profitability despite the decline in revenue and profit [2] - David Medical specializes in obstetric and pediatric care equipment, minimally invasive surgical instruments, and emergency ICU products, with key products including incubators and neonatal monitoring devices [1]

Core Viewpoint - David Medical (300314) announced that its wholly-owned subsidiary, Weierkaidi, has recently obtained three acceptance notices from the Zhejiang Provincial Drug Administration for new medical devices [1] Group 1: Product Details - The acceptance numbers are 20254019912, 20254019913, and 20254019722 [1] - The products include a disposable lung nodule localization puncture needle, a disposable electronic ureteral renal pelvis endoscope catheter, and a portable electronic endoscope image processor [1] - All registered products are classified as Class II medical devices [1] Group 2: Financial Impact - The acceptance of these product registration applications will not have an impact on the company's recent performance [1]

证券代码：300314 证券简称：戴维医疗 公告编号：2025-034 宁波戴维医疗器械股份有限公司 关于全资子公司申报医疗器械注册获得受理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）全资子公司宁波 维尔凯迪医疗器械有限公司（以下简称"维尔凯迪"）于近日取得由浙江省 药品监督管理局颁发的3项《受理通知书》，受理号为：械受20254019912、 械受20254019913、械受20254019722。具体情况如下： | 序号 | 产品名称 | 注册分 类 | | 临床用途 | | --- | --- | --- | --- | --- | | 1 | | | | 本产品适用于肺结节患者接受胸腔镜手术前的 CT | | | 一次性使用肺结节定 位穿刺针 | II | 类 | 引导下的肺结节定位，带线锚钩留置体内时间小于 | | | | | | 24 小时。 | | 2 | 一次性使用电子输尿 管肾盂内窥镜导管 | II | 类 | 本产品与本公司电子内窥镜图像处理器配合使用， 通过视频监视器提供影像，用 ...